1. Introduction {#sec1}
===============

The incidence of obesity and metabolic associated disorders, such as cardiovascular diseases, type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD), increase worldwide [@bib1], [@bib2], [@bib3]. Furthermore, there are no effective long-term non-surgical treatments for obesity and metabolic associated disorders [@bib4]. However, accumulating evidence points towards nuclear receptors (NRs) as potential molecular treatment targets [@bib5], [@bib6]. The NRs superfamily comprises 48 transcription factors in humans, which are involved in the regulation of a wide range of physiologic and pathophysiologic processes (i.e. development, circadian rhythm, response to steroid hormones, inflammation, obesity, diabetes, NAFLD, and cancer) [@bib7], [@bib8], [@bib9], [@bib10].

The retinoic acid-related orphan receptor α (RORα; NR1F1) is a NR that has been implicated in the regulation of a wide variety of metabolic pathways, including lipid, glucose and steroid metabolism [@bib11], [@bib12], [@bib13]. The initial indications that RORα can affect metabolic processes originate mainly from a natural occurring mutant mouse, the Staggerer mouse, which results in a loss of function [@bib14]. Staggerer mice are protected against diet-induced obesity and associated complications (i.e., adipose tissue inflammation, NAFLD, and impaired glucose metabolism), but also have cerebral phenotypes including impaired locomotion [@bib15], [@bib16]. However, activation of RORα with synthetic ligands also improves NAFLD by reducing hepatic oxidative stress and inflammation suggesting a potential beneficial role of RORα activation on obesity and metabolic diseases [@bib17], [@bib18], [@bib19].

In order to elucidate the role of RORα in obesity and metabolic diseases, tissue specific knockout models have recently been developed. Liver-specific ablation of RORα deteriorates metabolic profile in terms of adiposity, liver steatosis, inflammation and hepatic insulin resistance, when mice were fed a high fat diet (60% of energy from fat and 20% from carbohydrates) [@bib20], [@bib21]. These findings suggest a central role of RORα in the regulation of hepatic lipid and glucose metabolism. To further extend and validate the role of RORα on glucose and lipid metabolism, we generated an independent liver-specific RORα deficient strain that was metabolically phenotyped on both chow and western-style diet (WSD; 40% of energy from fat and 40% from carbohydrate and 20% protein).

2. Materials and methods {#sec2}
========================

2.1. Mice experiments {#sec2.1}
---------------------

Mice harbouring *loxP* sequences flanking exon 3, the first common exon coding for both isoform 1 and 4, were generated ([Figure 1](#fig1){ref-type="fig"}A). Deletion of the 86 bp exon 3 led to a frame shift resulting in a premature stop codon. Potential translated truncated proteins would be composed of 88 and 32 amino acids instead of 523 and 467 for isoform, 1 and 4 respectively. No functional domain would be present on these putative proteins. Generation of the strain was completed by homologous recombination in C57BL/6J embryonic stem cells followed by microinjection into C57BL/6J blastocysts. The resulting new-borns were crossed with C57BL/6 Flp delete mice to allow the excision of the neomycin selection cassette.Figure 1**Generation of liver-specific RORα knock out mice**. Schematic representation of the *Rora* gene-targeting strategy (A, see methods section for details). Expression level of *Rora* in the liver, ileum, white adipose tissue (WAT), and brain in RORα^fl/fl^ and RORα^LKO^ mice (B, 3--8 mice per group). Protein expression level of RORα and actin in liver extract from RORα^fl/fl^ and RORα^LKO^ mice (C). Data are plotted as mean -- SEM. \*\*\*p \< 0.001.Figure 1

Albumin-Cre mice were purchased from The Jackson Laboratory. Cre efficacy and specificity towards hepatocytes was confirmed by breading the mice with ROSA^mT/mG^ mice (data not shown). 8-weeks old male RORα^LKO^ and RORα^fl/fl^ littermate were fed a chow diet (Labdiet) or WSD (Harland, TD.96132, 40% fat, 40% sugar, 20% proteins) *ad libitum* for 12 weeks. MRI, insulin, glucose and pyruvate tolerance tests, and measurements of insulin levels were performed as earlier described [@bib22]. Briefly, insulin, glucose and pyruvate tolerance tests were performed by injecting insulin (0.75 U/kg body weight), glucose (2 g/kg body weight) or pyruvate (2 g/kg weight) respectively, intraperitoneally after a 4 (ITT and GTT) or 12 (PTT) h fast. Tail blood samples were collected at 0, 15, 30, 60, 90 and 120 min and blood glucose levels were determined using a glucose meter (Accu-Check Aviva, Roche). Insulin was measured with ELISA (Crystal Chem) according to the manufacturers\' protocols. All experiments including tissue harvesting were performed at the same time of the day (12.00 PM). The local ethics committee in Gothenburg approved all animal experiments.

2.2. Analysis of liver lipids content {#sec2.2}
-------------------------------------

Lipids were extracted using the BUME method [@bib23]. The cholesteryl esters, triglycerides and free cholesterol were analyzed using straight phase HPLC coupled to evaporative light scattering detection according to previous work [@bib24]. Briefly, the extract was evaporated under nitrogen and reconstituted in 500 μl heptane:isopropanol \[9:1\]. Cholesteryl esters, triglycerides, and free cholesterol were separated using straight-phase HPLC (Sunfire 2.1 × 100 mm, Waters) coupled to an evaporative light-scattering detector (PL-ELS 1000, Polymer Laboratories), as described previously [@bib24]. Quantification was made using external standards (Larodan Fine Chemicals).

2.3. Primary hepatocytes {#sec2.3}
------------------------

Primary hepatocytes were isolated from RORα^LKO^ and RORα^fl/fl^ littermates mice by digesting liver with perfusion of collagenase type IV, as described previously [@bib25]. After perfusion, 16 × 10^5^ cells were plated on collagen-coated 60 mm dishes in Dulbecco\'s modified Eagle\'s medium (DMEM)/F12 (Thermo Fisher) supplemented with fetal bovine serum (Thermo Fisher), penicillin/streptomycin, and 100 nM dexamethasone (Sigma Aldrich). After 4 h, the medium was changed to DMEM/F12 containing penicillin/streptomycin and then cells were harvested after 18h.

2.4. Preparation of protein extracts and immunoblotting {#sec2.4}
-------------------------------------------------------

RORα deletion in the liver was evaluated by extracting proteins from the snap-frozen liver or primary cells with lysis buffer, as described previously [@bib26] and immunoblotting with anti-RORα (Abcam, ab60134, 1:300 dilution), GADPH (Cell Signaling \#2118, 1:1000 dilution), and anti-actin (Cell Signaling \#4970, 1:1000 dilution) antibody.

2.5. Quantitative RT-PCR {#sec2.5}
------------------------

Total RNA was isolated using RNeasy kit with DNase treatment (Qiagen) and cDNA templates were generated using the high-capacity cDNA reverse transcription kit using random hexamers (Applied Biosystems). qRT-PCR assays were performed in 10 μl reactions with SYBR Green Master Mix buffer (Thermo Scientific). Gene expression data were normalized to the ribosomal protein L32. Primer sequences used are listed in [Supplementary Table 1](#appsec1){ref-type="sec"} (Sigma--Aldrich).

2.6. Statistical analysis {#sec2.6}
-------------------------

Data are presented as mean - SEM. Analyses between groups were performed by Student\'s t-test using GraphPad Prism 7 software.

3. Results {#sec3}
==========

3.1. Generation of mice with a hepatocyte specific RORα deletion {#sec3.1}
----------------------------------------------------------------

We generated mice with a hepatocyte specific *Rora* deletion of by introducing *loxP* sites flanking exon 3 of the *Rora* allele and crossing them with mice expressing Cre under the albumin promotor ([Figure 1](#fig1){ref-type="fig"}A and [Supplementary Fig. 1A](#appsec1){ref-type="sec"}).

Analyses of *Rora* expression by qRT-PCR in the liver, ileum, white adipose tissue (WAT), and brain, as well as RORα protein levels by Western blotting, confirmed a selective and specific liver deletion in RORα^LKO^ mice compared to littermate RORα^fl/fl^ mice ([Figure 1](#fig1){ref-type="fig"}B--C). Liver RT-qPCR analysis showed that there was a trend (p = 0.057) towards a compensatory increased expression of *Rorc* by the selective and specific liver RORα deletion ([Supplementary Fig. 1B](#appsec1){ref-type="sec"}). *Rorb* was not detectable in the livers (data not shown). Moreover, the expression of *Rev-erba*, one of the known *RORs* target genes, was reduced by the selective and specific liver RORα deletion ([Supplementary Fig. 1B](#appsec1){ref-type="sec"}). The expression of other *RORs* target genes (i.e. *Rev-erbb*, *Pparg*, *Cyp7b1*, *and Lxra)* was not affected by the selective and specific liver RORα deletion ([Supplementary Fig. 1B](#appsec1){ref-type="sec"}).

To further confirm a specific hepatocyte RORα deletion, we isolated primary hepatocytes from RORα^LKO^ mice and littermate RORα^fl/fl^ mice. Analyses of *Rora* expression by qRT-PCR as well as RORα protein levels by Western blotting, confirmed a specific RORα hepatocyte deletion in RORα^LKO^ mice compared to littermate RORα^fl/fl^ mice ([Supplementary Figs. 1C--D](#appsec1){ref-type="sec"}). Mice with a specific liver RORα deletion displayed a normal fertility and fecundity generating an equal number of male and female pups during RORα^LKO^ and RORα^fl/fl^ cross-breading.

3.2. RORα hepatic deletion does not affect glucose and lipid metabolism in mice fed chow diet {#sec3.2}
---------------------------------------------------------------------------------------------

Weight gain was monitored of 8-week-old male RORα^LKO^ and littermate RORα^fl/fl^ mice on chow diet for 12 weeks. We did not observe any significant differences in weight gain ([Figure 2](#fig2){ref-type="fig"}A), whole body adiposity determined by MRI ([Figure 2](#fig2){ref-type="fig"}B) or liver, WAT, spleen and cecum weights ([Figure 2](#fig2){ref-type="fig"}C). Liver RT-qPCR analysis as well as liver lipid measurements did not reveal any differences in lipid metabolism genes nor in cholesterol, cholesteryl ester or triglyceride levels between RORα^LKO^ and RORα^fl/fl^ littermates ([Figure 2](#fig2){ref-type="fig"}D and [Supplementary Fig. 2](#appsec1){ref-type="sec"}).Figure 2**RORα hepatic deletion does not affect glucose and lipid metabolism in mice fed chow diet**. Body weight (A), body composition (B), relative organ weights (C), liver cholesterol, cholesteryl esters, triglycerides levels (D), fasting glucose (E) and insulin levels (F), intraperitoneal glucose (G), insulin (H), and pyruvate (I) tolerance test in RORα^fl/fl^ and RORα^LKO^ male mice fed 12 weeks chow diet (n = 7--8 mice per group). Data are plotted as mean -- SEM.Figure 2

Fasting glucose and insulin levels as well as glucose levels during glucose-, insulin-, and pyruvate tolerance tests did not demonstrate any differences between RORα^LKO^ and RORα^fl/fl^ littermates ([Figure 2](#fig2){ref-type="fig"}E--I). Similar findings where obtained for female mice (see [Supplementary Fig. 3](#appsec1){ref-type="sec"}).

Taken together, our findings suggest that hepatocyte RORα deletion does not affect glucose and lipid metabolism on chow diet neither in males nor in females.

3.3. RORα hepatic deletion does not affect glucose and lipid metabolism in mice fed Western style diet {#sec3.3}
------------------------------------------------------------------------------------------------------

To further study the effect of RORα on metabolic associated disorders, we fed 8-week-old RORα^LKO^ and littermate RORα^fl/fl^ male mice with a WSD for 12 weeks. We did not observe any significant differences in weight gain ([Figure 3](#fig3){ref-type="fig"}A), whole body adiposity measured with MRI ([Figure 3](#fig3){ref-type="fig"}B) or liver, WAT, spleen or cecum weights ([Figure 3](#fig3){ref-type="fig"}C) suggesting that RORα does not affect diet-induced obesity. Liver RT-qPCR analysis as well as liver lipid measurements did not reveal any differences in in lipid metabolism genes nor in cholesterol, cholesteryl esters or triglyceride levels between RORα^LKO^ and RORα^fl/fl^ littermates ([Figure 3](#fig3){ref-type="fig"}D and [Supplementary Fig. 4](#appsec1){ref-type="sec"}).Figure 3**RORα hepatic deletion does not affect glucose and lipid metabolism in mice fed western-style diet (WSD).** Body weight (A), body composition (B), relative organ weights (C), liver cholesterol, cholesteryl esters, triglycerides levels (D), fasting glucose (E) and insulin levels (F) intraperitoneal glucose (G) insulin (H) and pyruvate (I) tolerance test in RORα^fl/fl^ and RORα^LKO^ male mice fed 12 weeks WSD (n = 8--12 mice per group). Data are plotted as mean -- SEM.Figure 3

Next, we assessed whether RORα contributes to glucose metabolism during WSD by analyzing fasting glucose and insulin levels as well as performing glucose-, insulin- and pyruvate tolerance tests. We did not observe any differences between RORα^LKO^ and RORα^fl/fl^ littermates ([Figure 2](#fig2){ref-type="fig"}E--I). Similar findings were obtained when we used female mice (see [Supplementary Fig. 5](#appsec1){ref-type="sec"}).

Taken together, our findings suggest that a hepatocyte RORα deletion does not affect glucose and lipids metabolism on WSD in both males and females.

4. Discussion {#sec4}
=============

NRs have been shown to play a crucial role in the regulation of glucose and lipid metabolism. Evidences from the RORα whole body knockout (Staggerer) mice have pointed towards RORα as a potential molecular target for the treatment of metabolic diseases [@bib14], [@bib15], [@bib16]. However, the improved metabolic phenotype of Staggerer mice is highly affected by the staggering phenotype induced by the cerebellum RORα deletion [@bib14], [@bib15], thus it is difficult to evaluate the role of RORα in metabolic active tissues, such as the liver. Here, by generating a liver specific RORα knockout mouse model, we did not detect any effects of RORα liver deletion on glucose or lipids metabolism on chow diet or after a WSD exposure.

Our data are in contrast with recent published data that showed that liver-specific ablation of RORα dramatically worsens metabolic profiles in mice eg. increased adiposity, liver fat accumulation, inflammation, and hepatic insulin resistance, when mice are fed a high fat diet [@bib20], [@bib21]. Several factors should be taken into account when comparing the discrepancy between the distinct phenotype reported by other groups and our present study. First, we targeted RORα exon 3 while the Cre-lox system used by others targeted exon 4 and 4--5, leaving the exon 3 that encodes the beginning of the DNA binding domain. Although the stability of potentially produced recombinant proteins, which in our experience usually is low, we cannot exclude that the generation of different truncated proteins containing a portion of the DNA binding domain may explain some of the divergent results between the studies. Importantly, we demonstrated an almost complete elimination of RORα in hepatocytes similar to other groups and also a significant effect on some of the known RORα target genes [@bib20], [@bib21], [@bib27], [@bib28]. Second, we challenged our mice with WSD while other reports used HFD. Importantly, it has been well-documented that, despite containing fewer calories, WSD induces more pronounced steatosis and liver inflammation compared with HFD [@bib29], [@bib30]. Thus, it may be plausible that in our model, the effect of WSD on steatosis and inflammation overwhelms the effect of RORα liver deletion.

In support to our findings *Zhang* et al. recently reported that the single knockout of RORα or RORγ in hepatocyte has almost no effect on liver gene expression while the double deletion of both RORα and RORγ in hepatocytes has a substantial impact on gene expression profiles, increases lipogenesis and therefore predisposes to HFD-induced steatosis [@bib31]. RORα and RORγ bind to the same response element and are both highly expressed in liver. Thus, deletion of only one of them may not be sufficient to induce a metabolic phenotype due to their functional redundancy. In our experimental model upon deletion of RORα, we observed a trend towards increased *Rorc* expression, which may be a compensation for the lack of RORα activity. Taken together, it is thus likely that double targeting of RORα and RORγ may be required for achieving maximum effect.

Moreover, it is known that RORα is a clock gene involved in circadian rhythm regulation [@bib31], [@bib32]. In an attempt to reduce experimental variation all metabolic phenotyping was performed at the same time of the day. Thus we cannot exclude that the discrepancy between our data and previous published data may be due to differences in experimental set up such as time of analyses.

5. Conclusions {#sec5}
==============

In conclusion, our data show that the deletion of RORα in the liver does not affect glucose or lipid metabolism during WSD in mice. Further studies testing the role of liver RORα or the double RORα and RORγ deletion in different dietary settings are needed to further elucidate the role of RORα on obesity and metabolic associated disorders.
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Appendix A. Supplementary data {#appsec2}
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The following are the Supplementary data to this article:Multimedia component 1Multimedia component 1**Supplementary figure 1. Generation of liver-specific RORα knock out mice**. PCR analyses (A) of genomic DNA extracted from tails of wild type (RORα^−/-^), heterozygote (RORα^−/fl^), homozygote (RORα^fl/fl^) mice. (B) Relative mRNA expression for *Rorc* (Retinoic acid-related orphan receptor gamma), *Rev-erba (Nuclear Receptor Subfamily 1 Group D Member 1)*, *Rev-erbb (Nuclear Receptor Subfamily 1 Group D Member 2)*, *Pparg* (Peroxisome proliferator-activated receptor gamma), *Cyp7b1* (25-hydroxycholesterol 7-alpha-hydroxylase), and *Lxra* (Liver X receptor alpha) in RORα^fl/fl^ and RORα^LKO^ male mice (n = 7--8 mice per group). (C) Relative mRNA expression for *Rora* and proteins levels for RORα (D) in primary hepatocytes isolated from RORα^fl/fl^ and RORα^LKO^ mice (n = 3 mice per group). Data are plotted as mean -- SEM. \*p \< 0.05, \*\*\*p \< 0.001.**Supplementary figure 2. RORα hepatic deletion does not affect lipogenic gene expression in the liver on chow diet**. Relative mRNA expression for *Scd1* (Stearoyl-CoA desaturase), *Acaca* (Acetyl-CoA carboxylase), *Fasn* (Fatty acid synthase), *Srebp1c* (sterol regulatory element-binding protein 1c) in RORα^fl/fl^ and RORα^LKO^ male mice on chow diet (n = 4 mice per group). Data are plotted as mean -- SEM.**Supplementary figure 3. RORα hepatic deletion does not affect glucose or lipid metabolism in female mice fed chow diet**. Body weight (A), body composition (B), relative organ weights (C), liver cholesterol, cholesteryl esters, triglycerides levels (D), fasting glucose (E) and insulin levels (F), intraperitoneal glucose (G), and insulin (H), tolerance test in RORα^fl/fl^ and RORα^LKO^ female mice fed 12 weeks chow diet (n = 3--6 mice per group). Data are plotted as mean -- SEM.**Supplementary figure 4. RORα hepatic deletion does not affect lipogenic gene expression in the liver on western style diet**. Relative mRNA expression for *Sdc1* (Stearoyl-CoA desaturase), *Acaca* (Acetyl-CoA carboxylase), *Fasn* (Fatty acid synthase), *Srebp1c* (sterol regulatory element-binding protein 1c) in RORα^fl/fl^ and RORα^LKO^ male mice on western style diet (n = 4 mice per group). Data are plotted as mean -- SEM.**Supplementary Figure 5. RORα hepatic deletion does not affect glucose and lipid metabolism in female mice fed western-style diet (WSD)**. Body weight (A), body composition (B), relative organ weights (C), liver cholesterol, cholesteryl esters, triglycerides levels (D), fasting glucose (E) and insulin levels (F) intraperitoneal glucose (G) insulin (H) and pyruvate (I) tolerance test in RORα^fl/fl^ and RORα^LKO^ female mice fed 12 weeks WSD (n = 9--11 mice per group). Data are plotted as mean -- SEM.
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